BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 32453653)

  • 1. Effects of CYP3A5, ABCB1 and POR*28 polymorphisms on pharmacokinetics of tacrolimus in the early period after renal transplantation.
    Ling J; Dong LL; Yang XP; Qian Q; Jiang Y; Zou SL; Hu N
    Xenobiotica; 2020 Dec; 50(12):1501-1509. PubMed ID: 32453653
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Population pharmacokinetic analysis and dosing guidelines for tacrolimus co-administration with Wuzhi capsule in Chinese renal transplant recipients.
    Jing Y; Kong Y; Hou X; Liu H; Fu Q; Jiao Z; Peng H; Wei X
    J Clin Pharm Ther; 2021 Aug; 46(4):1117-1128. PubMed ID: 33768546
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of CYP3A5 genotypes, ABCB1 C3435T and G2677T/A polymorphism on pharmacokinetics of Tacrolimus in Chinese adult liver transplant patients.
    Zhu L; Yang J; Zhang Y; Jing Y; Zhang Y; Li G
    Xenobiotica; 2015; 45(9):840-6. PubMed ID: 25869250
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prediction of the tacrolimus population pharmacokinetic parameters according to CYP3A5 genotype and clinical factors using NONMEM in adult kidney transplant recipients.
    Han N; Yun HY; Hong JY; Kim IW; Ji E; Hong SH; Kim YS; Ha J; Shin WG; Oh JM
    Eur J Clin Pharmacol; 2013 Jan; 69(1):53-63. PubMed ID: 22660440
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of ABCB1, CYP3A4*18B and CYP3A5*3 genotypes with the pharmacokinetics of tacrolimus in healthy Chinese subjects: a population pharmacokinetic analysis.
    Shi XJ; Geng F; Jiao Z; Cui XY; Qiu XY; Zhong MK
    J Clin Pharm Ther; 2011 Oct; 36(5):614-24. PubMed ID: 21916909
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multidrug resistance-associated protein 2 (MRP2/ABCC2) haplotypes significantly affect the pharmacokinetics of tacrolimus in kidney transplant recipients.
    Ogasawara K; Chitnis SD; Gohh RY; Christians U; Akhlaghi F
    Clin Pharmacokinet; 2013 Sep; 52(9):751-62. PubMed ID: 23633119
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tacrolimus population pharmacokinetics according to CYP3A5 genotype and clinical factors in Chinese adult kidney transplant recipients.
    Zhang HJ; Li DY; Zhu HJ; Fang Y; Liu TS
    J Clin Pharm Ther; 2017 Aug; 42(4):425-432. PubMed ID: 28401703
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The genetic polymorphisms of POR*28 and CYP3A5*3 significantly influence the pharmacokinetics of tacrolimus in Chinese renal transplant recipients.
    Zhang JJ; Liu SB; Xue L; Ding XL; Zhang H; Miao LY
    Int J Clin Pharmacol Ther; 2015 Sep; 53(9):728-36. PubMed ID: 26227094
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Population pharmacokinetic analysis of tacrolimus in Mexican paediatric renal transplant patients: role of CYP3A5 genotype and formulation.
    Jacobo-Cabral CO; García-Roca P; Romero-Tejeda EM; Reyes H; Medeiros M; Castañeda-Hernández G; Trocóniz IF
    Br J Clin Pharmacol; 2015 Oct; 80(4):630-41. PubMed ID: 25846845
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tacrolimus population pharmacokinetic models according to CYP3A5/CYP3A4/POR genotypes in Chinese Han renal transplant patients.
    Zhu W; Xue L; Peng H; Duan Z; Zheng X; Cao D; Wen J; Wei X
    Pharmacogenomics; 2018 Aug; 19(13):1013-1025. PubMed ID: 30040022
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Effect of Weight and CYP3A5 Genotype on the Population Pharmacokinetics of Tacrolimus in Stable Paediatric Renal Transplant Recipients.
    Prytuła AA; Cransberg K; Bouts AH; van Schaik RH; de Jong H; de Wildt SN; Mathôt RA
    Clin Pharmacokinet; 2016 Sep; 55(9):1129-43. PubMed ID: 27138785
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of CYP3A4 and CYP3A5 polymorphisms on tacrolimus pharmacokinetics in Chinese adult renal transplant recipients: a population pharmacokinetic analysis.
    Zuo XC; Ng CM; Barrett JS; Luo AJ; Zhang BK; Deng CH; Xi LY; Cheng K; Ming YZ; Yang GP; Pei Q; Zhu LJ; Yuan H; Liao HQ; Ding JJ; Wu D; Zhou YN; Jing NN; Huang ZJ
    Pharmacogenet Genomics; 2013 May; 23(5):251-61. PubMed ID: 23459029
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tacrolimus pharmacokinetics and pharmacogenetics: influence of adenosine triphosphate-binding cassette B1 (ABCB1) and cytochrome (CYP) 3A polymorphisms.
    Op den Buijsch RA; Christiaans MH; Stolk LM; de Vries JE; Cheung CY; Undre NA; van Hooff JP; van Dieijen-Visser MP; Bekers O
    Fundam Clin Pharmacol; 2007 Aug; 21(4):427-35. PubMed ID: 17635182
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Population pharmacokinetic-pharmacogenetic model of tacrolimus in the early period after kidney transplantation.
    Han N; Ha S; Yun HY; Kim MG; Min SI; Ha J; Lee JI; Oh JM; Kim IW
    Basic Clin Pharmacol Toxicol; 2014 May; 114(5):400-6. PubMed ID: 24238261
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CYP3A and ABCB1 genetic polymorphisms on the pharmacokinetics and pharmacodynamics of tacrolimus and its metabolites (M-I and M-III).
    Yoon SH; Cho JH; Kwon O; Choi JY; Park SH; Kim YL; Yoon YR; Won DI; Kim CD
    Transplantation; 2013 Mar; 95(6):828-34. PubMed ID: 23364483
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of POR and CYP3A5 Polymorphisms on Trough Concentration to Dose Ratio of Tacrolimus in the Early Post-operative Period Following Kidney Transplantation.
    Phupradit A; Vadcharavivad S; Ingsathit A; Kantachuvesiri S; Areepium N; Sra-Ium S; Auamnoy T; Sukasem C; Sumethkul V; Kitiyakara C
    Ther Drug Monit; 2018 Oct; 40(5):549-557. PubMed ID: 29878980
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of Postoperative Day and NR1I2 on Tacrolimus Clearance in Chinese Liver Transplant Recipients-A Population Model Approach.
    Lu Y; Xu L; Cui J; Shen S; Li X
    Clin Pharmacol Drug Dev; 2021 Nov; 10(11):1385-1394. PubMed ID: 34133842
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative clinical trial of the variability factors of the exposure indices used for the drug monitoring of two tacrolimus formulations in kidney transplant recipients.
    Marquet P; Albano L; Woillard JB; Rostaing L; Kamar N; Sakarovitch C; Gatault P; Buchler M; Charpentier B; Thervet E; Cassuto E
    Pharmacol Res; 2018 Mar; 129():84-94. PubMed ID: 29229354
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Population pharmacokinetics and Bayesian estimation of tacrolimus exposure in Chinese liver transplant patients.
    Chen B; Shi HQ; Liu XX; Zhang WX; Lu JQ; Xu BM; Chen H
    J Clin Pharm Ther; 2017 Dec; 42(6):679-688. PubMed ID: 28833329
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Population pharmacokinetics of tacrolimus in adult kidney transplant patients: impact of CYP3A5 genotype on starting dose.
    Bergmann TK; Hennig S; Barraclough KA; Isbel NM; Staatz CE
    Ther Drug Monit; 2014 Feb; 36(1):62-70. PubMed ID: 24089074
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.